↓ Skip to main content

Dove Medical Press

Article Metrics

What is this page? Embed badge

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes

Overview of attention for article published in Therapeutics and Clinical Risk Management, January 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
1 policy source
twitter
1 tweeter

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
49 Mendeley
Summary Policy documents Twitter Dimensions citations
Title
Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
Published in
Therapeutics and Clinical Risk Management, January 2015
DOI 10.2147/tcrm.s51474
Pubmed ID
25673994
Authors

Sanjay Chotirmall, Mazen Al-Alawi, Thomas McEnery, Noel Gerard McElvaney

View on publisher site

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 49 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 20%
Other 6 12%
Student > Ph. D. Student 6 12%
Researcher 6 12%
Student > Master 5 10%
Other 6 12%
Unknown 10 20%
Readers by discipline Count As %
Medicine and Dentistry 20 41%
Agricultural and Biological Sciences 8 16%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Biochemistry, Genetics and Molecular Biology 3 6%
Nursing and Health Professions 1 2%
Other 4 8%
Unknown 9 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2021.
All research outputs
#7,272,754
of 22,953,506 outputs
Outputs from Therapeutics and Clinical Risk Management
#390
of 1,271 outputs
Outputs of similar age
#100,999
of 353,984 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#12
of 19 outputs
Altmetric has tracked 22,953,506 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 1,271 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,984 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.

This page is hosted by Altmetric on behalf of Dove Medical Press.